Ruiz-Villaverde, R.; Rodriguez Fernandez-Freire, L.; Font-Ugalde, P.; Galan-Gutierrez, M.
Tildrakizumab: Efficacy, Safety and Survival in Mid-Term (52 Weeks) in Three Tertiary Hospitals in Andalucia (Spain). J. Clin. Med. 2022, 11, 5098.
https://doi.org/10.3390/jcm11175098
AMA Style
Ruiz-Villaverde R, Rodriguez Fernandez-Freire L, Font-Ugalde P, Galan-Gutierrez M.
Tildrakizumab: Efficacy, Safety and Survival in Mid-Term (52 Weeks) in Three Tertiary Hospitals in Andalucia (Spain). Journal of Clinical Medicine. 2022; 11(17):5098.
https://doi.org/10.3390/jcm11175098
Chicago/Turabian Style
Ruiz-Villaverde, Ricardo, Lourdes Rodriguez Fernandez-Freire, Pilar Font-Ugalde, and Manuel Galan-Gutierrez.
2022. "Tildrakizumab: Efficacy, Safety and Survival in Mid-Term (52 Weeks) in Three Tertiary Hospitals in Andalucia (Spain)" Journal of Clinical Medicine 11, no. 17: 5098.
https://doi.org/10.3390/jcm11175098
APA Style
Ruiz-Villaverde, R., Rodriguez Fernandez-Freire, L., Font-Ugalde, P., & Galan-Gutierrez, M.
(2022). Tildrakizumab: Efficacy, Safety and Survival in Mid-Term (52 Weeks) in Three Tertiary Hospitals in Andalucia (Spain). Journal of Clinical Medicine, 11(17), 5098.
https://doi.org/10.3390/jcm11175098